Liver function abnormality following treatment with antithymocyte globulin for aplastic anaemia

Antithymocyte globulin and transplants for aplastic anemia.

have completed a study on the use of antithymocyte globulin (ATG) as part of the conditioning regimen for severe aplastic anemia (SAA) patients, undergoing an allogeneic stem cell transplant (HSCT) from matched sibling (MSD) or unrelated (UD) donors. The Authors have found that rabbit ATG (thymoglobulin, Sanofi, France), as compared to horse ATG (ATGAM, Pfizer, USA) is associated with less acut...

Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia.

Graves disease following rabbit antithymocyte globulin treatment of severe aplastic anemia in a Korean child

Antithymocyte globulin (ATG) is used as an immunosuppressive treatment (IST) to deplete clonal suppressor T cells in patients with severe aplastic anemia (SAA). The depletion of suppressor T cells by ATG may affect the activation of B cells, which results in an increased risk for autoimmune conditions. A 12-year-old boy was diagnosed with idiopathic SAA. As he did not have an human leukocyte an...

Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party.

Rabbit antithymocyte globulin (rATG; thymoglobulin, Genzyme) in combination with cyclosporine, as first-line immunosuppressive therapy, was evaluated prospectively in a multicenter, European, phase 2 pilot study, in 35 patients with aplastic anemia. Results were compared with 105 age- and disease severity-matched patients from the European Blood and Marrow Transplant registry, treated with hors...

Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia.

Immunosuppressive therapy can produce hematologic improvement in a large proportion of patients with severe aplastic anemia. Antithymocyte globulin (ATG) is the current treatment of choice for patients who do not have histocompatible sibling donors or who are otherwise inegligible for allogeneic bone marrow transplantation. About 50% of patients respond to an initial course of ATG, and many non...